Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites

Journal of Medicinal Chemistry

Volumn 49, Issue 19, 2006, Pages 5710-5727

  Glenn, Matthew P ^a   Chang, Sung Youn ^a   Hornéy, Carrie ^b   Rivas, Kasey ^b   Yokoyama, Kohei ^b   Pusateri, Erin E ^a   Fletcher, Steven ^a   Cummings, Christopher G ^a   Buckner, Frederick S ^b   Pendyala, Prakash R ^d   Chakrabarti, Debopam ^d   Sebti, Saïd M ^c   Gelb, Michael ^b   Van Voorhis, Wesley C ^b   Hamilton, Andrew D ^a  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR PROTEIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOXICITY; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PLASMODIUM; PLASMODIUM FALCIPARUM;

ADMINISTRATION, ORAL; ANILINE COMPOUNDS; ANIMALS; ANTIMALARIALS; BINDING SITES; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; FARNESYLTRANSTRANSFERASE; HUMANS; IMIDAZOLES; MALE; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; NITRILES; PLASMODIUM FALCIPARUM; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 33748858487     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060081v     Document Type: Article

References (26)

1. Sachs, J.; Malaney, P. The economic and social burden of malaria. Nature 2002, 415, 680-685.
2. Olliaro, P. L.; Bloland, P. B. Clinical and public health implications of antimalarial drug resistance. Antimalar. Chemother. 2001, 65-83.
3. Wiesner, J.; Ortmann, R.; Jomaa, H.; Schlitzer, M. New antimalarial drugs. Angew. Chem., Int. Ed. 2003, 42, 5274-5293.
4. May, J.; Meyer, C. G. Chemoresistance in falciparum malaria. Trends Parasitol. 2003, 19, 432-435.
5. Ridley, R. G. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 2002, 415, 686-693.
6. Rosenthal, P. J. Antimalarial drug discovery: old and new approaches. J. Exp. Biol. 2003, 206, 3735-3744.
7. Chakrabarti, D.; Azam, T.; DelVecchio, C.; Qiu, L.; Park, Y.-I.; Allen, C. M. Protein prenyl transferase activities of Plasmodium falciparum. Mol. Biochem. Parasitol. 1998, 94, 175-184.
8. Nallan, L.; Bauer, K. D.; Bendale, P.; Rivas, K.; Yokoyama, K.; Hornéy, C. P.; Pendyala, P. R.; Floyd, D.; Lombardo, L. J.; Williams, D. K.; Hamilton, A.; Sebti, S.; Windsor, W. T.; Weber, P. C.; Buckner, F. S.; Chakrabarti, D.; Gelb, M. H.; Van Voorhis, W. C. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J. Med. Chem. 2005, 48, 3704-3713.
9. Clough, B.; Wilson, R. J. M. Antibiotics and plasmoidal plastid organelle. Antimalar. Chemother. 2001, 265-286.
10. Loyevsky, M.; Gordeuk, V. R. Iron chelators. Antimalar. Chemother. 2001, 307-324.
11. Gelb, M. H.; Van Voorhis, W. C.; Buckner, F. S.; Yokoyama, K.; Eastman, R.; Carpenter, E. P.; Panethymitaki, C.; Brown, K. A.; Smith, D. F. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol. Biochem. Parasitol. 2003, 126, 155-163.
12. Chakrabarti, D.; Da Silva, T.; Barger, J.; Paquette, S.; Patel, H.; Patterson, S.; Allen, C. M. Protein farnesyltransferase and protein prenylation in Plasmodium falciparum. J. Biol. Chem. 2002, 277, 42066-42073.
13. (a) Ohkanda, J.; Lockman, J. W.; Yokoyama, K.; Gelb, M. H.; Croft, S. L.; Kendrick, H.; Harrell, M. I.; Feagin, J. E.; Blaskovich, M. A.; Sebti, S. M.; Hamilton, A. D. Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity. Bioorg. Med. Chem. Lett. 2001, 11, 761-764.
14. (b) Ohkanda, J.; Knowles, D. B.; Blaskovich, M. A.; Sebti, S. M.; Hamilton, A. D. Inhibitors of protein farnesyltransferase as novel anticancer agents. Curr. Top. Med. Chem. 2002, 2, 303-323.
15. Glenn, M. P.; Chang, S. Y.; Hucke, O.; Verlinde, C. L.; Rivas, K.; Hornéy, C.; Yokoyama, K.; Buckner, F. S.; Pendyala, P. R.; Chakrabarti, D.; Gelb, M.; Van Voorhis, W. C.; Sebti, S. M.; Hamilton, A. D. Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites. Angew. Chem., Int. Ed. 2005, 44, 4903-4906.
16. Wiesner, J.; Kettler, K.; Sakowski, J.; Ortmann, R.; Katzin, A. M.; Kimura, E. A.; Silber, K.; Klebe, G.; Jomaa, H.; Schlitzer, M. Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo. Angew. Chem., Int. Ed. 2004, 43, 251-254.
17. Hunt, J. T.; Ding, C. Z.; Batorsky, R.; Bednarz, M.; Bhide, R.; Cho, Y.; Chong, S.; Chao, S.; Gullo-Brown, J.; Guo, P.; Kim, S. H.; Lee, F. Y.; Leftheris, K.; Miller, A.; Mitt, T.; Patel, M.; Penhallow, B. A.; Ricca, C.; Rose, W. C.; Schmidt, R.; Slusarchyk, W. A.; Vite, G.; Manne, V. Discovery of (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl) -4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J. Med. Chem. 2000, 43, 3587-3595.
18. Sebti, S. M.; Hamilton, A. D. Farnesyltransferase and geranylgeranyl-transferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000, 19, 6584-6593.
19. Strickland, C. L.; Windsor, W. T.; Syto, R.; Wang, L.; Bond, R.; Wu, Z.; Schwartz, J.; Le, H. V.; Beese, L. S.; Weber, P. C. Crystal Structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analog. Biochemistry 1998, 37, 16601-16611.
20. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
21. Eastman, R. T.; White, J.; Hucke, O.; Bauer, K.; Yokoyama, K.; Nallan, L.; Chakrabarti, D.; Verlinde, C. L.; Gelb, M. H.; Rathod, P. K.; Van Voorhis, W. C. Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J. Biol. Chem. 2005, 280, 13554-13559.
22. Seto, Y.; Guengerich, F. P. Partitioning between N-dealkylation and N-oxygenation in the oxidation of N,N-dialkylarylamines catalyzed by cytochrome P450 2B1. J. Biol. Chem. 1993, 268, 9986-9997.
23. Irvine, J. D.; Takahashi, L.; Lockhart, K.; Cheong, J.; Tolan, J. W.; Selick, H. E.; Grove, J. R. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 1999, 88, 28-33.
24. Artursson, P.; Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 1991, 175, 880-885.
25. Trager, W.; Jensen, J. B. Human malaria parasites in continuous culture. Science 1976, 193, 673-675.
26. Van der Veken, P.; Senten, K.; Kertesz, I.; De Meester, I.; Lambeir, A.-M.; Maes, M. B.; Scharpe, S.; Haemers, A.; Augustyns, K. Fluoroolefins as peptidomimetic inhibitors of dipeptidyl peptidases. J. Med. Chem. 2005, 48, 1768-1780.